MANNKIND CORP Form 8-K August 26, 2013

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 26, 2013

MannKind Corporation

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction

000-50865 (Commission 13-3607736 (IRS Employer

of incorporation) File Number) Identification No.)

28903 North Avenue Paine

Valencia, California 91355 (Address of principal executive offices) (Zip Code) Registrant s Telephone Number, Including Area Code: (661) 775-5300

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- " Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure.

On August 26, 2013, MannKind Corporation posted Frequently Asked Questions about the Affinity 1 and Affinity 2 Trials on its corporate website www.mannkindcorp.com.

The information in this Current Report is being furnished and shall not be deemed filed for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended.

Item 9.01 Financial Statements and Exhibits

- (d) Exhibits. The following exhibit is furnished herewith:
- 99.1 Frequently Asked Questions about the Affinity 1 and Affinity 2 Trials.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MANNKIND CORPORATION

By: /s/ David Thomson, Ph.D., J.D. Name: David Thomson, Ph.D., J.D.

Title: Corporate Vice President, General Counsel and

Secretary

Dated: August 26, 2013